European markets have recently experienced a boost, with the pan-European STOXX Europe 600 Index rising by 1.18% amid easing trade tensions and optimism over potential U.S. interest rate cuts. In this context, penny stocks—often smaller or newer companies—remain a notable area of interest for their unique combination of affordability and growth potential. Despite being an outdated term, these stocks can still offer significant opportunities when backed by strong financials, as demonstrated by the examples we'll explore in this article.
Top 10 Penny Stocks In Europe
| Name | Share Price | Market Cap | Rewards & Risks |
| Ariston Holding (BIT:ARIS) | €4.60 | €1.59B | ✅ 4 ⚠️ 3 View Analysis > |
| Mistral Iberia Real Estate SOCIMI (BME:YMIB) | €1.05 | €22.87M | ✅ 2 ⚠️ 5 View Analysis > |
| Lucisano Media Group (BIT:LMG) | €1.00 | €14.86M | ✅ 3 ⚠️ 4 View Analysis > |
| Maps (BIT:MAPS) | €3.38 | €44.89M | ✅ 4 ⚠️ 2 View Analysis > |
| Angler Gaming (NGM:ANGL) | SEK3.60 | SEK269.95M | ✅ 4 ⚠️ 2 View Analysis > |
| Angler Gaming (DB:0QM) | €0.37 | €307.44M | ✅ 3 ⚠️ 1 View Analysis > |
| Cellularline (BIT:CELL) | €3.09 | €65.17M | ✅ 4 ⚠️ 2 View Analysis > |
| ForFarmers (ENXTAM:FFARM) | €4.75 | €419.83M | ✅ 4 ⚠️ 1 View Analysis > |
| Deceuninck (ENXTBR:DECB) | €2.08 | €287.17M | ✅ 3 ⚠️ 1 View Analysis > |
| Netgem (ENXTPA:ALNTG) | €0.95 | €32.04M | ✅ 4 ⚠️ 2 View Analysis > |
Click here to see the full list of 336 stocks from our European Penny Stocks screener.
Let's take a closer look at a couple of our picks from the screened companies.
I.M.D. International Medical Devices (BIT:IMD)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: I.M.D. International Medical Devices S.p.A. operates in the medical devices sector and has a market cap of €26.50 million.
Operations: The company generates revenue of €39.74 million from its Medical Imaging Systems segment.
Market Cap: €26.5M
I.M.D. International Medical Devices S.p.A., with a market cap of €26.50 million, operates in the medical devices sector and generates revenue of €39.74 million from its Medical Imaging Systems segment. The company has more cash than total debt, and its short-term assets significantly exceed both short- and long-term liabilities, indicating solid financial stability. While IMD's earnings growth has lagged behind the industry average, it maintains high-quality earnings and covers interest payments comfortably. Despite trading well below estimated fair value, IMD's Return on Equity is low at 9.6%, and profit margins have slightly decreased year-on-year.
- Get an in-depth perspective on I.M.D. International Medical Devices' performance by reading our balance sheet health report here.
- Assess I.M.D. International Medical Devices' future earnings estimates with our detailed growth reports.
Hove (CPSE:HOVE)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Hove A/S develops, produces, and supplies advanced lubrication solutions for heavy machinery both in Denmark and internationally, with a market cap of DKK115.37 million.
Operations: Hove A/S has not reported any specific revenue segments.
Market Cap: DKK115.37M
Hove A/S, with a market cap of DKK115.37 million, has shown significant earnings growth of 1138.2% over the past year, surpassing its five-year average and the machinery industry benchmark. The company's financial health is robust, with short-term assets exceeding both short- and long-term liabilities and more cash than total debt. Recent earnings reports reveal increased sales to DKK108.31 million for the half-year ending June 2025, alongside improved net income margins from last year. However, Hove's share price remains highly volatile despite trading at a substantial discount to estimated fair value.
- Navigate through the intricacies of Hove with our comprehensive balance sheet health report here.
- Review our historical performance report to gain insights into Hove's track record.
Molecular Partners (SWX:MOLN)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Molecular Partners AG is a clinical-stage biotechnology company focused on designing and developing ankyrin repeat protein therapeutics for oncology treatment in Switzerland, with a market cap of CHF97.29 million.
Operations: Molecular Partners AG does not report distinct revenue segments.
Market Cap: CHF97.29M
Molecular Partners AG, with a market cap of CHF97.29 million, is a pre-revenue biotechnology company focused on oncology treatments. Despite being unprofitable and having volatile share prices, the company has no debt and maintains a stable cash runway for over two years. Recent developments include promising preclinical data for MP0726 and positive Phase 1/2a trial results for MP0533 in AML treatment, indicating potential therapeutic advancements. The board and management team are experienced, though earnings are forecast to decline over the next three years. Molecular Partners' short-term assets significantly exceed its liabilities, supporting financial stability amidst ongoing research efforts.
- Take a closer look at Molecular Partners' potential here in our financial health report.
- Examine Molecular Partners' earnings growth report to understand how analysts expect it to perform.
Next Steps
- Embark on your investment journey to our 336 European Penny Stocks selection here.
- Curious About Other Options? The end of cancer? These 26 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if I.M.D. International Medical Devices might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com